- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02326857
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment
Background:
- Researchers want to learn more about breast cancer in Latin American women. They also want to learn how and why women respond differently to standard treatment. Tissue and blood samples from women with breast cancer are needed to study this disease in order to find new ways to prevent, diagnose, and treat it.
Objective:
- To learn more about the biology and genetics of breast cancer in Latin American women.
Eligibility:
- Latin American women age 18 and older of all ethnic backgrounds who have clinical stage II or III breast cancer. They must still be active and able to self-care.
Design:
- Participants are only agreeing to have extra tissue or blood samples collected. They are also letting tissue left over from surgery be used for research. No procedures outside of standard care will be done.
- Participants may have a medical history, physical exam, and blood tests. They may have a pregnancy test. They may have an ultrasound, mammogram, and other scans. They may have an intravenous needle placed in an arm vein.
- Participants may have a core biopsy. For this, a needle is inserted into the breast. A piece of tissue is extracted.
- Participants who have chemotherapy may have blood taken after treatment/before surgery. Tissue may also be collected.
- Participants will complete a questionnaire. It will ask about their social and economic background. It will ask about their family history of cancer. It will also ask about access to diagnosis and treatment of breast cancer.
- Participants may be followed for up to 5 years.
연구 개요
상태
정황
상세 설명
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Guadalajara, 멕시코
- Universidad de Guadalajara
-
Guadalajara, 멕시코
- Instituto Jalisciense de Cancerologia
-
Sonora, 멕시코
- Universidad de Sonora
-
-
-
-
-
Rio de Janeiro, 브라질
- Instituto Nacional de Cancer (INCA)
-
Sao Paulo, 브라질
- Instituto do C(SqrRoot) ncer do Estado de S(SqrRoot) o Paulo
-
-
-
-
-
Buenos Aires, 아르헨티나
- Instituto Leloir
-
-
-
-
-
Montevideo, 우루과이
- Institito Nacional de C(SqrRoot)(Degree)ncer
-
Montevideo, 우루과이
- Instituto Pasteur de Montevideo
-
-
-
-
-
Santiago, 칠레
- Instituto de Salud Publica
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
- ELIGIBILITY CRITERIA:
ELIGIBILITY CRITERIA FOR PART A OF THE STUDY:
INCLUSION CRITERIA:
- Women age greater than or equal to 18 years.
- AJCC 7 clinical stage II or III breast cancer. Clarification: Participants with clinical stage II breast cancer who are later classified as histologically-confirmed stage I will remain on study; participants who are later classified as histologically-confirmed stage IV breast cancer will be taken off study.
- Biopsy-accessible breast tumor or participant candidates for primary surgery.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 1.
EXCLUSION CRITERIA:
- Prior history of non-breast malignancy (excluding in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to enrollment in this study.
- Bilateral invasive or in-situ breast cancer.
- Inflammatory breast cancer.
- Clinical or radiological evidence of distant metastases by computed tomography (CT), chest X-ray, abdominal/thoracic ultrasound, bone scan, and/or liver function tests including total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), within ranges defined in eligibility criteria for Part B of the study.
- Prior hormone therapy, chemotherapy, biologic, targeted therapies, or radiation therapy for this malignancy. Prior bisphosphonate therapy is allowed.
- Pregnant and lactating women: Effects on a developing human fetus of chemotherapeutic agents at the recommended therapeutic dose remain incompletely defined. For this reason and because these agents may be teratogenic, women of child-bearing potential must agree to use adequate contraception (double barrier methods of birth control or abstinence) prior to study entry and for the duration of study treatment phase. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
- Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapeutic agents, women who are breastfeeding will be excluded. If a participant is of child-bearing potential (women are not considered of childbearing potential if they are at least 2 years postmenopausal and/or surgically sterile), she must have documented negative serum or negative urine pregnancy tests within 14 days of entry to the study (i.e., within 14 days of signing the informed consent document).
- Subjects with psychiatric illness and/or other specific situations that would limit compliance with study requirements and compromise participant follow-up.
- Lack of ability to understand and willingness to sign a written informed consent document.
Note: Subjects who were enrolled prior to this amendment will be considered eligible even if the HIV/Hep C and pregnancy test were not preformed due to each country standards.
ELIGIBILITY CRITERIA FOR PART B OF THE STUDY:
Participants, who successfully enrolled into the first part of the study and who, according to local institutional guidelines, are candidates for neoadjuvant chemotherapy will participate in Part B of the study. Participants must also meet the inclusion and exclusion criteria described below.
INCLUSION CRITERIA:
- Histologically confirmed new primary adenocarcinoma of the breast AJCC 7 clinical stage II or III. All histological types are included Hormone status: Any tumor ER/PgR status, any HER2/neu status as measured by local hospital pathology laboratory following US LA CRN standard operating procedures (SOPs).
Normal organ and marrow function as defined below:
- Absolute neutrophil count greater than or equal to 1500/microL
- Platelets greater than or equal to 100,000/microL
- Total bilirubin within normal institutional limits, unless participant has Gilbert s disease, for which bilirubin must be less than or equal to 2.0 times upper limits of normal (ULN)
- AST serum glutamic-oxaloacetic transaminase (SGOT)/ALT serum glutamic-pyruvic transaminase (SGPT) less than or equal to 1.5 times institutional ULN
- ALP less than or equal to 2.5 times institutional ULN
- Creatinine less than or equal to 1.5 times institutional ULN
- Negative serum or urine beta-human chorionic gonadotropin (HCG), unless participant is post-hysterectomy or menopausal.
EXCLUSION CRITERIA:
- Uncontrolled or severe cardiac disease. Baseline left ventricular ejection fraction (LVEF) by nuclear imaging or echocardiography must be within normal institutional limits.
- Use of any investigational agents within 30 days of starting standard chemotherapy treatment.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to chemotherapeutic agents or accompanying supportive medications.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness and/or other specific situations that would limit compliance with study requirements and compromise participant follow-up.
INCLUSION OF WOMEN AND MINORITIES:
-Latin American women with breast cancer of all ethnic backgrounds will be included in this study as participants. There are no expected racial/ethnic differences in the recruitment effort.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
Women with breast cancer
Observational study of women with Stage II/III locally advanced breast cancer in Latin America
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Characterize distribution of invasive breast cancer stage II and III molecular profiles
기간: 2 years post accrual closure
|
This project will provide valuable information on the effectiveness of standard chemotherapy in Latin American women.
|
2 years post accrual closure
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Association of molecular profile with tumor histological type, size,lymph node status and surrogate markers
기간: 2 years post accrual closure
|
2 years post accrual closure
|
Proportion of participants in each molecular profile who achieve pCR to neoadjuvant chemotherpay
기간: 2 years post accrual closure
|
2 years post accrual closure
|
RCB following neoadjuvant chemotherapy
기간: 2 years post accrual closure
|
2 years post accrual closure
|
Predictive and prognostic gene expression signatures
기간: 2 years post accrual closure
|
2 years post accrual closure
|
Survival-OS, DFS, and TFF
기간: 2 years post accrual closure
|
2 years post accrual closure
|
Demographic and epidemiological characteristics of the population by molecular profile
기간: 2 years post accrual closure
|
2 years post accrual closure
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Thomas G Gross, M.D., National Cancer Institute (NCI)
간행물 및 유용한 링크
일반 간행물
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093.
- Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 1;24(7):1037-44. doi: 10.1200/JCO.2005.02.6914.
- Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009 Jun;18(6):883-93. doi: 10.1089/jwh.2008.1127.
- Llera AS, Abdelhay ESFW, Artagaveytia N, Daneri-Navarro A, Muller B, Velazquez C, Alcoba EB, Alonso I, Alves da Quinta DB, Binato R, Bravo AI, Camejo N, Carraro DM, Castro M, Castro-Cervantes JM, Cataldi S, Cayota A, Cerda M, Colombo A, Crocamo S, Del Toro-Arreola A, Delgadillo-Cisterna R, Delgado L, Dreyer-Breitenbach M, Fejerman L, Fernandez EA, Fernandez J, Fernandez W, Franco-Topete RA, Gabay C, Gaete F, Garibay-Escobar A, Gomez J, Greif G, Gross TG, Guerrero M, Henderson MK, Lopez-Munoz ME, Lopez-Vazquez A, Maldonado S, Moran-Mendoza AJ, Nagai MA, Oceguera-Villanueva A, Ortiz-Martinez MA, Quintero J, Quintero-Ramos A, Reis RM, Retamales J, Rivera-Claisse E, Rocha D, Rodriguez R, Rosales C, Salas-Gonzalez E, Sanchotena V, Segovia L, Sendoya JM, Silva-Garcia AA, Trinchero A, Valenzuela O, Vedham V, Zagame L; United States-Latin American Cancer Research Network (US-LACRN); Podhajcer OL. The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients. Front Oncol. 2022 Mar 22;12:835626. doi: 10.3389/fonc.2022.835626. eCollection 2022.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- 999915055
- 15-C-N055
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해